Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Bigal, M. E.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bigal, M. E.
Related Collections
Right arrow All Headache
Right arrow Migraine
Right arrow Cohort studies
NEUROLOGY 2008;70:1525-1533
© 2008 American Academy of Neurology

Prevalence and characteristics of allodynia in headache sufferers

A population study

M. E. Bigal, MD, PhD, S. Ashina, MD, R. Burstein, M. L. Reed, PhD, D. Buse, PhD, D. Serrano, MA, R. B. Lipton, MD On behalf of the AMPP Group*

From the Departments of Neurology (M.E.B., S.A., D.B., R.B.L.) and Epidemiology and Population Health (R.B.L.), Albert Einstein College of Medicine, Bronx; The Montefiore Headache Center (M.E.B., R.B.L.), Bronx, NY; The New England Center for Headache (M.E.B.), Stamford, CT; Harvard Medical School (R.B.), Cambridge, MA; Vedanta Research (M.L.R., D.S.), Chapel Hill, NC; and Merck Research Laboratories (M.E.B.), Whitehouse Station, NJ.

Address correspondence and reprint requests to Dr. Marcelo E. Bigal, Global Director, Scientific Affairs, Neuroscience, One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889-0100 Marcelo_Bigal{at}merck.com

Objective: The authors estimated the prevalence and severity of cutaneous allodynia (CA) in individuals with primary headaches from the general population.

Methods: We mailed questionnaires to a random sample of 24,000 headache sufferers previously identified from the population. The questionnaire included the validated Allodynia Symptom Checklist (ASC) as well as measures of headache features, disability, and comorbidities. We modeled allodynia as an outcome using headache diagnosis, frequency and severity of headaches, and disability as predictor variables in logistic regression. Covariates included demographic variables, comorbidities, use of preventive medication, and use of opioids.

Results: Complete surveys were returned by 16,573 individuals. The prevalence of CA of any severity (ASC score ≥3) varied with headache type. Prevalence was significantly higher in transformed migraine (TM, 68.3%) than in episodic migraine (63.2%, p < 0.01) and significantly elevated in both of these groups compared with probable migraine (42.6%), other chronic daily headaches (36.8%), and severe episodic tension-type headache (36.7%). The prevalence of severe CA (ASC score ≥9) was also highest in TM (28.5%) followed by migraine (20.4%), probable migraine (12.3%), other chronic daily headaches (6.2%), and severe episodic tension-type headache (5.1%). In the migraine and TM groups, prevalence of CA was higher in women and increased with disability score. Among migraineurs, CA increased with headache frequency and body mass index. In all groups, ASC scores were higher in individuals with major depression.

Conclusions: Cutaneous allodynia (CA) is more common and more severe in transformed migraine and migraine than in other primary headaches. Among migraineurs, CA is associated with female sex, headache frequency, increased body mass index, disability, and depression.

Abbreviations: AMPP = American Migraine Prevalence and Prevention; ASC = Allodynia Symptom Checklist; CA = cutaneous allodynia; CDH = chronic daily headaches; MIDAS = Migraine Disability Assessment; O-CDH = other chronic daily headaches; PM = probable migraine; PR = prevalence ratio; QST = quantitative sensory testing; S-ETTH = severe episodic tension-type headache; TM = transformed migraine.


*Members of the AMPP Advisory Group are listed in the appendix.

Disclosure: This study was sponsored by the National Headache Foundation (NHF) through a grant from Ortho-McNeil Neurologics, Inc. (OMP). Dr. Bigal and Dr. Lipton received grant support from OMP for research projects other than this study. Dr. Bigal and Dr. Lipton are on the advisory board and give lectures supported by OMP. Dr. Bigal is currently an employee of Merck Research Laboratories.

Received July 3, 2007. Accepted in final form October 29, 2007.




This article has been cited by other articles:


Home page
JWatch NeurologyHome page
Cutaneous Allodynia in Primary Headache
Journal Watch Neurology, June 24, 2008; 2008(624): 4 - 4.
[Full Text]


Home page
BMJHome page
R. W Evans
Treating migraine in the emergency department
BMJ, June 14, 2008; 336(7657): 1320 - 1320.
[Full Text] [PDF]


Home page
Journal Watch DermatologyHome page
Skin Hypersensitivity and Chronic Headaches
Journal Watch Dermatology, May 2, 2008; 2008(502): 2 - 2.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.